Skip to main content
. 2017 Nov 9;117(12):1768–1776. doi: 10.1038/bjc.2017.382

Table 2. Treatment upon first progression.

  CAIRO3
AIO 0207
  Observation (n=279) FP+Bev (n=278) Total (n=557) Observation (n=158) FP+Bev (n=156) Total (n=314)
Anti-EGFR therapy 48 (17) 54 (19) 102 (18) 40 (25) 44 (28) 84 (27)
Irinotecan 165 (59) 162 (58) 327 (59) 96 (61) 85 (54) 181 (58)
Mitomycin 1 (0.4) 1 (0.4) 2 (0.4) 13 (8) 13 (8) 26 (8)
Regorafenib 2 (0.7) 1 (0.4) 3 (0.5) 9 (6) 13 (8) 22 (7)
Aflibercept/placeboa 8 (3) 4 (1.4) 12 (2) 12 (8) 6 (4) 18 (6)
Ramucirumab/placebo 2 (0.7) 2 (0.7) 4 (0.7) 1 (1) 2 (1) 3 (1)
Tegafur-uracil 3 (1) 5 (2) 8 (1)
Cisplatin 1 (0.4) 1 (0.2)
Paclitaxel 1 (0.4) 1 (0.2)
Experimental study drug 9 (3) 4 (1) 13 (2) 1 (1) 1 (0.3)
Dendritic cell vaccinations 1 (0.4) 1 (0.2)
No other agent than FP, Ox, Bev 104 (37) 101 (36) 205 (37) 60 (38) 65 (42) 125 (40)

Abbreviations: Bev=bevacizumab; FP=fluoropyrimidine; Ox=oxaliplatin.

The data are n (%) unless otherwise specified.

a

No placebo for AIO 0207.